AstraZeneca agrees to USD 2 billion Summit deal. AstraZeneca stock trades below EUR 143.25

Published on 10/01/2026 at 10:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue hit USD 15.38 billion, up 5.00 percent at constant exchange rates. AstraZeneca stock costs EUR 141.98 after EUR 143.25 on October 1, 2026.

Wissenschaftler im weißen Kittel arbeiten in modernem Pharma-Forschungslabor — AstraZeneca plc (ISIN GB0009895292) betreibt moderne Forschungslabore für pharmazeutische Wirkstoffentwicklung und klinische Studien weltweit, Illustration mit AI erstellt.

AstraZeneca (ISIN GB0009895292) agreed to invest USD 2.00 billion in Summit Therapeutics through preferred stock, according to 24/7 Wall St. on September 30, 2026. AstraZeneca stock was trading at EUR 141.98 at Lang & Schwarz on October 1, 2026, down 0.89 percent versus the prior close of EUR 143.25.

Summit deal adds oncology exposure

The preferred stock converts into Summit common shares equal to about 12.00 percent of the company at a conversion price of USD 18.36, the report said. AstraZeneca receives no licensing rights to Summit's ivonescimab, while the collaboration includes a trial combining ivonescimab with AstraZeneca's experimental sonesitatug vedotin in gastrointestinal cancers.

The financial commitment gives Summit cash of USD 2.50 billion, up from USD 690.70 million, according to 24/7 Wall St. The funding reduces the immediate need for additional share sales, but the clinical outcome remains central because the larger HARMONi-3 trial data is due by the end of 2026.

Revenue growth supports the backdrop

AstraZeneca reported total revenue of USD 15.38 billion in the second quarter of 2026, up 5.00 percent at constant exchange rates, while reported earnings per share stood at USD 1.61, according to StockQuay. For the first half of 2026, total revenue reached USD 30.67 billion and reported earnings per share were USD 3.60, putting the Summit investment alongside a business that is still expanding its top line.

Analyst targets remain above the quote

J.P. Morgan maintained a Buy rating and set a GBp 160.00 price target on September 29, 2026, according to Markets Insider. A separate September 30 overview from Futu News listed Goldman Sachs as initiating coverage with a Buy rating and showed targets from USD 191.80 to USD 267.19.

Stock stays below the prior close

AstraZeneca is listed on the London Stock Exchange under ticker AZN.L, and its market capitalization was USD 250.4 billion as of September 30, 2026. The company belongs to the healthcare sector and drug manufacturers industry, while the Summit transaction makes oncology pipeline execution the key counterweight to the group's diversified revenue base.

The further course of trading is shown by the continuously updated real-time quote of AstraZeneca stock.